EGFR and glioblastoma: However, a novel prognostic GBM signature could be generated to evaluate its progression and to select effective therapies, which would include the quantification of C3G and Vimentin levels, ERK activation, and/or the evaluation of the switching from EGFR to FGFR signalling, among others.